Biopharmaceutical company ThromboGenics has confirmed the launch of Jetrea (ocriplasmin) in the UK, ahead of the rest of Europe.
In partnership with Alcon, the introduction of Jetrea onto the UK market will see the drug used in the treatment of vitreomacular traction (VMT) and macular hole. Despite now being available in the UK, a decision on the availability of the drug on the NHS is not expected until the latter quarter of 2013.
As a division of Novartis, Alcon acquired the rights to commercialise Jetrea outside of America in March 2012. In March this year, the European Commission approved the drug for the treatment of vitreomacular traction (VMT) and macular hole across the EU.
CEO of ThromboGenic, Dr Patrik De Haes said: “The launch of Jetrea in Europe by Alcon so shortly after gaining European approval is testimony of our joint commitment to ensuring patients in Europe have access to this innovative drug as soon as possible.”